BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 34241676)

  • 1. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell and Antibody Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Cohort of Kidney Transplant Recipients.
    Devresse A; Saad Albichr I; Georgery H; Yombi JC; De Greef J; Belkhir L; Mzougui S; Scohy A; Darius T; Buemi A; Goffin E; Kabamba B; Kanaan N
    Transplantation; 2021 Oct; 105(10):e142-e143. PubMed ID: 34310103
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
    Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H
    J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients.
    Sattler A; Schrezenmeier E; Weber UA; Potekhin A; Bachmann F; Straub-Hohenbleicher H; Budde K; Storz E; Proß V; Bergmann Y; Thole LM; Tizian C; Hölsken O; Diefenbach A; Schrezenmeier H; Jahrsdörfer B; Zemojtel T; Jechow K; Conrad C; Lukassen S; Stauch D; Lachmann N; Choi M; Halleck F; Kotsch K
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34101623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients.
    Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F
    J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
    McKenzie DR; Muñoz-Ruiz M; Monin L; Alaguthurai T; Lechmere T; Abdul-Jawad S; Graham C; Pollock E; Graham R; Sychowska K; Seow J; Tremain C; Gousis C; Domingo-Vila C; Cooper J; Vidler J; Owczarczyk K; Swampillai A; Kristeleit H; Malim MH; Fields P; Patten PEM; Papa S; North BV; Tree T; Doores KJ; Hayday AC; Irshad S
    Cancer Cell; 2021 Nov; 39(11):1445-1447. PubMed ID: 34678151
    [No Abstract]   [Full Text] [Related]  

  • 10. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.
    Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C
    Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant.
    Murray SM; Barbanti M; Campbell C; Brown A; Chen L; Dhanapal J; Tseu B; Pervaiz O; Peters L; Springett S; Danby R; Adele S; Phillips E; Malone T; Amini A; Stafford L; Deeks AS; Dunachie S; Klenerman P; Peniket A; Barnes E; Kesavan M
    Br J Haematol; 2022 Aug; 198(4):668-679. PubMed ID: 35655410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.
    De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ
    Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
    Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
    EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.
    Hod T; Ben-David A; Olmer L; Levy I; Ghinea R; Mor E; Lustig Y; Rahav G
    Transplantation; 2021 Nov; 105(11):e234-e243. PubMed ID: 34310101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.